Loading...
•
Dec 31, 2022
Supernus Q4 2022 Earnings Report
Announced fourth quarter and full year 2022 financial results, showing revenue growth driven by Qelbree and GOCOVRI.
Key Takeaways
Supernus Pharmaceuticals reported a 6% increase in net product sales for the fourth quarter of 2022, reaching $163.8 million, driven by growth in Qelbree and GOCOVRI sales. The company's full-year revenues reached a record $667.2 million, a 15% increase compared to the previous year. The company anticipates approximately 30% growth at the midpoint of full year 2023 total revenues guidance compared to full year 2022, excluding revenues of Trokendi XR®.
Fourth quarter Qelbree net product sales increased 29% compared to the third quarter of 2022.
Fourth quarter GOCOVRI net product sales increased 13% compared to the fourth quarter of 2021.
Total IQVIA prescriptions for Qelbree increased 24% in the fourth quarter of 2022 compared to the third quarter of 2022.
Operating earnings (GAAP) for the fourth quarter of 2022 was $34.3 million, compared to $6.1 million for the same period in 2021.
Revenue by Segment
Forward Guidance
The Company’s full year 2023 total revenue guidance represents approximately 30% growth at the midpoint compared to full year 2022, excluding revenues of Trokendi XR in both periods.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...